ELVN
HealthcareEnliven Therapeutics, Inc. · Biotechnology · $3B
What is Enliven Therapeutics, Inc.?
Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule inhibitors for cancer patients. Founded in 2020 and headquartered in Boulder, Colorado, the company is building a pipeline targeting specific cancer-driving genetic abnormalities.
Enliven Therapeutics discovers and develops small molecule kinase inhibitors designed to block the biological signals that drive certain cancers. Its lead candidates are currently in Phase 1 clinical trials — one targeting chronic myeloid leukemia and another targeting cancers with abnormal HER2 gene activity. As a clinical-stage company, Enliven does not yet generate product revenue; its value rests entirely on the progress and eventual success of its pipeline programs.
Enliven Therapeutics was founded in 2020 and is based in Boulder, Colorado.
- ELVN-001: Phase 1 inhibitor for chronic myeloid leukemia
- ELVN-002: Phase 1 inhibitor for HER2-abnormal cancers
- Small molecule kinase inhibitor discovery platform
- Oncology-focused precision medicine pipeline
Is ELVN a Good Stock to Buy?
UQS Score rates ELVN as Poor overall, reflecting the early-stage nature of its business and the significant uncertainties that come with a pre-revenue clinical pipeline.
The one area where ELVN stands out relative to its pillar profile is Risk, which is rated Good — suggesting the company's balance sheet and near-term financial structure carry less immediate distress than many clinical-stage peers.
Quality, Moat, and Growth are all rated Weak, which is expected for a company with no approved products or commercial revenue. Valuation is rated Elevated, meaning the current market price may already reflect optimistic pipeline assumptions.
See the full pillar breakdown and underlying financial metrics by signing up for a Pro account on uqs-score.com. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ELVN pay dividends?
No — Enliven Therapeutics, Inc. does not currently pay a dividend.
Enliven Therapeutics does not pay a dividend, which is standard for clinical-stage biopharmaceutical companies. All available capital is directed toward funding clinical trials, research operations, and pipeline development. Investors in ELVN are accepting pre-revenue risk in exchange for potential long-term upside tied to drug approval outcomes rather than income distributions.
When does ELVN report earnings?
Enliven Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a clinical-stage company, quarterly reports focus primarily on cash runway, operating expenses, and clinical trial progress rather than revenue or profitability. Investors should monitor pipeline milestones and cash position updates closely.
For the most recent quarter's results and pipeline updates, visit Enliven Therapeutics' investor relations page directly.
ELVN Price History
+57.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Enliven Therapeutics, Inc.?
Based on Enliven Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ELVN Long-term Outlook
Enliven's near-term trajectory is shaped almost entirely by clinical trial outcomes rather than traditional financial growth drivers. With Growth and Quality both rated Weak, the company is not expected to generate meaningful revenue in the near term. The Good Risk rating provides some reassurance around financial stability, but the Elevated Valuation label suggests the market may already be pricing in favorable trial results that have yet to materialize.
Growth drivers
- Positive Phase 1 data readouts for ELVN-001 or ELVN-002
- Potential partnership or licensing deals with larger pharmaceutical companies
- Expansion of the kinase inhibitor pipeline into additional oncology indications
Key risks
- Clinical trial failure or safety signals in either lead program
- Elevated valuation leaves little margin of safety if pipeline progress stalls
- Ongoing cash consumption with no product revenue to offset operating costs
ELVN vs Peers
Enliven operates in a competitive oncology drug development landscape alongside other clinical and commercial-stage specialty biopharmaceutical companies.
Tarsus has advanced further toward commercialization in its specialty therapeutic focus, giving it a different risk and revenue profile than pre-revenue Enliven.
Veradermics pursues a dermatology-focused pipeline, representing a different therapeutic area but a similarly early-stage development model.
Structure Therapeutics targets GPCR biology with small molecule drugs, competing for investor attention in the precision oncology and metabolic disease space.
Frequently Asked Questions
What does Enliven Therapeutics do?
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small molecule kinase inhibitors for cancer. Its two lead programs — ELVN-001 for chronic myeloid leukemia and ELVN-002 for HER2-abnormal cancers — are both in Phase 1 clinical trials. The company does not yet have any approved products or commercial revenue.
Does ELVN pay dividends?
No, Enliven Therapeutics does not pay a dividend. As a clinical-stage company with no product revenue, all capital is reinvested into research and clinical operations. Dividend payments are not typical for pre-commercial biopharmaceutical companies at this stage of development.
When does ELVN report earnings?
Enliven Therapeutics reports financial results on a quarterly basis, as required for US-listed public companies. For the exact timing of upcoming reports and the most recent quarterly results, check the investor relations section of the Enliven Therapeutics website.
Is ELVN a good stock to buy?
UQS Score rates ELVN as Poor overall, driven by Weak ratings across Quality, Moat, and Growth pillars. The Risk pillar is rated Good, but Valuation is Elevated. This profile reflects the high uncertainty of a pre-revenue clinical-stage company. The full pillar breakdown is available to Pro members on uqs-score.com.
Is ELVN overvalued?
The UQS Valuation pillar for ELVN is rated Elevated, which suggests the current market price may be pricing in optimistic pipeline outcomes ahead of confirmed clinical data. For clinical-stage biotechs, valuation is closely tied to trial progress rather than traditional earnings-based metrics.
How does ELVN compare to its competitors?
Compared to peers like Tarsus Pharmaceuticals, Veradermics, and Structure Therapeutics, Enliven is distinguished by its oncology kinase inhibitor focus and fully pre-revenue status. Each competitor operates in a different therapeutic niche or stage of development. The UQS platform scores each company independently across the same five pillars for a consistent comparison.
What is ELVN's market cap bracket?
Enliven Therapeutics is classified as a mid-cap company. This places it in a bracket that typically attracts both institutional and retail investor interest, though the clinical-stage nature of the business means its market cap reflects pipeline potential rather than current earnings power.
Who founded Enliven Therapeutics?
Enliven Therapeutics was founded in 2020. Detailed founding information, including the names of co-founders and the company's early history, is publicly available through the company's official website and SEC filings.
Is ELVN a long-term quality investment?
As a long-term quality indicator, ELVN's current UQS profile — with Weak scores across Quality, Moat, and Growth — reflects the inherent uncertainty of a company that has not yet reached commercialization. Long-term quality potential depends heavily on clinical trial outcomes and the company's ability to build durable competitive advantages over time.
What is the main competitive advantage of Enliven Therapeutics?
Enliven's potential competitive advantage lies in its targeted small molecule kinase inhibitor platform, which is designed to address specific cancer-driving genetic mutations. However, the UQS Moat pillar is currently rated Weak, reflecting that durable competitive advantages are difficult to establish before a company has approved products on the market.
What sector does ELVN belong to?
Enliven Therapeutics operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. Investors interested in this sector can explore other [healthcare stocks scored by UQS](/sector/healthcare) for broader context and comparison.
Unlock Full ELVN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access underlying financial metrics and trend data
- ✓Compare ELVN against scored sector peers
- ✓Track pipeline-stage risk indicators over time
- ✓Get the full analyst view available to Pro members
Pro Analysis
ELVN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | 13.5 | 0.0 | 14.0 | 1.8 | 64.1 | 0.0 | +0.4 |
| May 9, 2026 | 13.1 | 0.0 | 14.0 | 0.0 | 64.1 | 0.0 | -0.8 |
| Apr 22, 2026 | 13.9 | 0.0 | 14.0 | 1.8 | 67.2 | 0.0 | -0.1 |
| Apr 2, 2026 | 14.0 | 0.0 | 14.0 | 2.3 | 67.2 | 0.0 | — |
ELVN — Pillar Breakdown
Quality
— 0.0/100 (25%)Enliven Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 1.8/100 (20%)Enliven Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 64.1/100 (15%)Enliven Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Enliven Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 14/100 (25%)Enliven Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ELVN.
Score Composition
Financial Data
More Stock Analysis
How is the ELVN UQS Score Calculated?
The UQS (Unified Quality Score) for Enliven Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Enliven Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Enliven Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.